FindTrial
Sign In

Efficacy of Intracavernous Platelet-rich Plasma Injection in the Treatment of Erectile Dysfunction

Efficacy of Intracavernous Platelet-rich Plasma Injection in the Treatment of Erectile Dysfunction

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06942988
Enrollment
34
Registered
2025-04-24
Start date
2023-12-29
Completion date
2025-07-29
Last updated
2025-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Keywords

platelet-rich plasma, Erectile Dysfunction

Brief summary

Investigation of the efficacy of autologous platelet-rich plasma administration on the potency of patients with vasculogenic and/or neurogenic erectile dysfunction

Interventions

BIOLOGICALintracavernous platelet rich plasma therapy

intracavernous platelet-rich plasma therapy for erectile dysfunction

Sponsors

t-biyoteknoloji labaratuvar estetik medikal kozmetik san. ve tic. ltd. şti.
CollaboratorUNKNOWN
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

\- 1)40-70 years old male, sexually active heterosexual, 2) Patients with a diagnosis of mild to moderate erectile dysfunction (IIEF score between 8-21) according to the International Index of Erectile Function (IIEF) for at least 3 months, 3) Patients who cannot achieve an erection despite peroral PDE5 inhibitor and intracavernous alprostadil injection therapy

Exclusion criteria

1. Patients with psychogenic erectile dysfunction, 2) Patients with a history of priapism, penile fracture, peyronie, penile curvature 3) Patients with a history of radical prostatectomy, 4) Patients with a history of major pelvic trauma, surgery, radiotherapy, 5) Patients with a history of malignancy affecting survival, 6) Patients with severe psychiatric illness that impairs adherence to treatment, 7) Patients with any bleeding disorder or on anti-aggregants/coagulants.

Design outcomes

Primary

MeasureTime frameDescription
IIEF6 monthsTo observe the increase in the International Index of Erectile Function (IIEF) score after treatment compared to before treatment in patients.

Secondary

MeasureTime frameDescription
FSFI6 monthsTo observe FSFI score increases in patients' partners before and after treatment using the Female Sexual Function Inventory (FSFI).

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026